Regencell Bioscience (RGC)
(Delayed Data from NSDQ)
$4.74 USD
+1.03 (27.70%)
Updated Apr 17, 2024 03:53 PM ET
After-Market: $4.50 -0.24 (-5.01%) 5:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Regencell Bioscience Holdings Limited falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 6 | 8 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -6 | -8 | -1 | -1 | 0 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -6 | -8 | -1 | -1 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -8 | -1 | -1 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -6 | -7 | -1 | -1 | 0 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -7 | -1 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -6 | -8 | -1 | -1 | 0 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 13.01 | 12.81 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.58 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.45 | -0.58 | -0.13 | -0.08 | NA |
Fiscal Year end for Regencell Bioscience Holdings Limited falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |